

Sopherion Therapeutics, Inc

It is currently my understanding that all active patients will be administratively taken off of the study. The company is interested in collecting overall survival for all patients through January 2011.

For now, business as usual until you receive further direction. It has been my pleasure working with you. I have worked with many CROS in my career and GCT is hands down the best!

Best regards,

Senior Director, Clinical Ops, November 12, 2010

Sopherion Therapeutics, Inc